2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
146 hedge funds and large institutions have $508M invested in 2seventy bio in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 55 increasing their positions, 21 reducing their positions, and 25 closing their positions.
162% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 21
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
80% more call options, than puts
Call options by funds: $656K | Put options by funds: $364K
60% more capital invested
Capital invested by funds: $317M → $508M (+$191M)
20% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 25
4% more funds holding
Funds holding: 141 → 146 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$42.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$16.4M |
| 4 |
O
OrbiMed
New York
|
+$15.4M |
| 5 |
Morgan Stanley
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
-$11.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.7M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$5.86M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.28M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.18M |
TSVT Hedge Fund Activity: Q1 2023 in Review
146 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q1 2023, worth a combined $508M — up 60% from $317M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new TSVT positions and 25 closed out — a net gain of 5 holders — while 55 added to existing stakes and 21 trimmed.
The largest buyer was Kynam Capital Management, opening a new position worth an estimated $42.7M. The largest seller was Madison Avenue Partners, exiting entirely with an estimated $11.2M sold.
- 146 institutional investors held 2seventy bio (TSVT) as of Q1 2023, up from 141 in Q4 2022.
- Funds reported $508M of 2seventy bio stock for Q1 2023, up 60% quarter-over-quarter.
- 30 funds opened new 2seventy bio positions in Q1 2023 and 25 closed out, a net change of +5 holders.
- The largest 2seventy bio buyer in Q1 2023 was Kynam Capital Management, an estimated $42.7M added.
- The largest 2seventy bio seller in Q1 2023 was Madison Avenue Partners, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2023.